

PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Xalkori Prior Authorization Policy

- Xalkori® (crizotinib capsules and oral pellets – Pfizer)

REVIEW DATE: 01/17/2024

OVERVIEW

Xalkori, an oral kinase inhibitor, is indicated for the following uses:¹

- **Anaplastic large cell lymphoma (ALCL)**, treatment of relapsed or refractory, systemic ALCL that is anaplastic lymphoma kinase (*ALK*)-positive in pediatric patients ≥ 1 year of age and young adults.
- **Inflammatory Myofibroblastic tumor (IMT)**, treatment of unresectable, recurrent, or refractory IMT that is *ALK*-positive in patients ≥ 1 year of age.
- **Non-small cell lung cancer (NSCLC)**, metastatic, whose tumors are *ALK*-positive or *c-rOS* proto-oncogene 1 (*ROS1*)-positive as detected by an FDA-approved test in adults.

Guidelines

Xalkori has been addressed in National Comprehensive Cancer Network (NCCN) guidelines.⁵⁻⁸

- **Histiocytic Neoplasms:** Guidelines (version 1.2023 – August 11, 2023) recommend Xalkori as a “useful in certain circumstances” treatment option for the following types of histiocytic neoplasm with *ALK* rearrangement/fusion: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease (category 2A).³
- **Inflammatory Myofibroblastic Tumor (IMT):** NCCN Soft Tissue Sarcoma guidelines (version 3.2023 – December 12, 2023) and NCCN Uterine Neoplasms guidelines (version 1.2024 – September 20, 2023) recommend Xalkori as a treatment option for IMT with *ALK* translocation.^{4,5}
- **Melanoma: Cutaneous:** Guidelines (version 3.2023 – October 27, 2023) recommend Xalkori as a treatment option for cutaneous melanoma with *ALK* or *ROS1* fusions.⁶ Case reports or limited clinical trial data have suggested activity for various gene fusions; Xalkori is noted for *ROS1* and *ALK* fusions.
- **NSCLC:** Guidelines (version 1.2024 – December 21, 2023) recommend Xalkori as a treatment option for *ROS1* rearrangement, *ALK* rearrangement-positive NSCLC, and as a treatment option for NSCLC with mesenchymal-epithelial transition (*MET*) exon 14 skipping mutation or high-level *MET* amplification.⁷
- **T-Cell Lymphoma:** Guidelines (version 1.2024 – December 21, 2023) recommend Xalkori as a treatment option for *ALK*-positive ALCL either as initial palliative-intent therapy or for relapsed or refractory disease.⁷ NCCN notes that Xalkori also demonstrated activity in adults with relapsed or refractory *ALK*-positive ALCL, after at least one line of prior cytotoxic therapy.⁸

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Xalkori. All approvals are provided for the duration noted below.

Automation: None.

01/17/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Xalkori is recommended in those who meet one of the following criteria:

FDA-Approved Indications

1. **Anaplastic Large Cell Lymphoma.** Approve for 1 year if the patient meets the following (A, B, and C):
 - A) Patient is ≥ 1 year of age; AND
 - B) Patient has anaplastic lymphoma kinase (*ALK*)-positive disease; AND
 - C) Patient meets one of the following (i or ii):
 - i. The medication is used for palliative-intent therapy; OR
 - ii. Patient has relapsed or refractory disease.
2. **Inflammatory Myofibroblastic Tumor.** Approve for 1 year if the patient meets the following (A, B, and C):
 - A) Patient is ≥ 1 year of age; AND
 - B) Patient has anaplastic lymphoma kinase (*ALK*)-positive disease; AND
 - C) Patient meets one of the following (i or ii):
 - i. Patient has advanced, recurrent, or metastatic disease; OR
 - ii. The tumor is inoperable.
3. **Non-Small Cell Lung Cancer – Anaplastic Lymphoma Kinase (*ALK*)-Positive.** Approve for 1 year if the patient meets the following (A, B, C, and D):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has advanced or metastatic disease; AND
 - C) Patient has anaplastic lymphoma kinase (*ALK*)-positive disease; AND
 - D) The mutation was detected by an approved test.
4. **Non-Small Cell Lung Cancer – *ROS1* Rearrangement-Positive.** Approve for 1 year if the patient meets the following (A, B, C, and D):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has advanced or metastatic disease; AND
 - C) Patient has *ROS1* rearrangement-positive disease; AND
 - D) The mutation was detected by an approved test.

Other Uses with Supportive Evidence

5. **Histiocytic Neoplasm.** Approve for 1 year if patient meets the following (A, B, and C).
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has anaplastic lymphoma kinase (*ALK*) rearrangement/fusion-positive disease; AND
 - C) Patient meets one of the following (i, ii, or iii):
 - i. Patient has Langerhans cell histiocytosis; OR
 - ii. Patient had Erdheim-Chester disease; OR
 - iii. Patient has Rosai-Dorfman disease.

Melanoma, Cutaneous. Approve for 1 year if patient meets the following (A and B):

- A) Patient is ≥ 18 years of age; AND
- B) Patient meets one of the following (i or ii):
 - i. Patient has anaplastic lymphoma kinase (*ALK*) fusion disease; OR
 - ii. Patient has *ROS1* fusion disease.

7. Non-Small Cell Lung Cancer with Mesenchymal Epithelial Transition (*MET*) Mutation. Approve for 1 year if the patient meets the following (A and B):

- A) Patient is ≥ 18 years of age; AND
- B) Patient meets one of the following (i or ii):
 - i. Patient has non-small cell lung cancer with high level *MET* amplification; OR
 - ii. Patient has non-small cell lung cancer with *MET* exon 14 skipping mutation.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Xalkori is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Xalkori® capsules and oral pellets [prescribing information]. New York, NY: Pfizer; September 2023.
2. The NCCN Drugs & Biologics Compendium. © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on January 12, 2024. Search term: crizotinib.
3. The NCCN Histiocytic Neoplasms Clinical Practice Guidelines in Oncology (version 1.2023 – August 11, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on January 14, 2024.
4. The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (version 3.2023 – December 12, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on January 14, 2023.
5. The NCCN Uterine Neoplasms Clinical Practice Guidelines in Oncology (version 1.2024 – September 20, 2023) © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on January 14, 2023.
6. The NCCN Melanoma: Cutaneous Clinical Practice Guidelines in Oncology (version 3.2023 – October 27, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on January 14, 2024.
7. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 1.2024 – December 21, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on January 14, 2024.
8. The NCCN T-Cell lymphomas Clinical Practice Guidelines in Oncology (version 1.2024 – December 21, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on January 14, 2024.